CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3-Reference-Cited by-同舟云学术

CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3

Published:2011-04 Issue:4 Volume:19 Page:541-555
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Chen Jingqi,Yao Yandan,Gong Chang,Yu Fengyan,Su Shicheng,Chen Jianing,Liu Bodu,Deng Hui,Wang Fengsong,Lin Ling,Yao Herui,Su Fengxi,Anderson Karen S.,Liu Qiang,Ewen Mark E.,Yao Xuebiao,Song Erwei

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference36 articles.

1. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells;Adema;Nature,1997

2. Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction;Amarilio;J. Biol. Chem.,2005

3. CC-chemokine ligand 18/pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders;Chang;Neuroscience,2010

4. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis;Condeelis;Cell,2006

5. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis;Coussens;Cell,2000

Cited by 524 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18;PLOS ONE;2024-09-11

2. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment;Biomarker Research;2024-09-03

3. Unveiling the contribution of tumor-associated macrophages in driving epithelial-mesenchymal transition: a review of mechanisms and therapeutic Strategies;Frontiers in Pharmacology;2024-09-02

4. Single-cell transcriptome analysis of macrophage subpopulations contributing to chemotherapy resistance in ovarian cancer;Immunobiology;2024-09

5. Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics;Heliyon;2024-09